Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

BIOVECTRA Announces Appointment of Steven M. Klosk and Gordon C. Mccauley to Board


BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.

"Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board of Directors," says Oliver Technow, CEO of BIOVECTRA. "BIOVECTRA's ambitious growth plans will be well-supported through the considerable leadership and expertise that I know each will contribute as directors with our board."

Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises. As President and CEO of adMare, Mr. McCauley leads its mission to build companies, ecosystems, and talent in the life sciences industry. adMare has over 25 portfolio companies that have attracted more than $1.4 billion of investment with a combined value of over $3 billion.

"I am excited to help as a director with BIOVECTRA," says Gordon McCauley. "What an excellent example of the type of world-leading companies we can build in Canada. I know BIOVECTRA leadership care deeply about producing high quality products to better serve patient care. I look forward to helping BIOVECTRA scale new heights."

Steven Klosk BS, JD is a consummate executive of the life sciences industry with over 25 years of experience of CDMO leadership. Mr. Klosk retired as CEO of Cambrex Corporation in 2020 after leading its sale to Permira, a global private equity firm. During his tenure Cambrex became a leading global and fully integrated supplier of drug substances, drug product and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets. The company grew to over 2,000 employees spanning a network of 12 manufacturing and research and development sites in North America and Europe.

"I am thrilled to serve on the board of directors of this thriving CDMO which places care for patients, clients, and its team as integral to BIOVECTRA's success," explains Steven Klosk. "This is an exciting time in the life sciences industry, and I look forward to working with the board to help BIOVECTRA reach its optimal success."

About BIOVECTRA

BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.


These press releases may also interest you

at 03:00
Following the inspiring opening speech, "Future Perspective of Cancer Immunotherapy," delivered by Nobel Prize and Tang Prize laureate Prof. Tasuku Honjo at the 14th Asia Pacific Federation of Pharmacologist Conference (APFP) on November 26, the 2020...

at 00:00
Trails Carolina, the leader in wilderness therapy for pre-teens and teens, teamed up with the Arkansas Institute of Developmental Science and the Center for Research, Assessment, and Treatment Efficacy to assess the impacts on youth and their...

26 nov 2021
Public Health Agency of Canada The Government of Canada is working with partners to protect the health and safety of Canadians and Temporary Foreign Workers in Canada, and to reduce the spread of COVID-19 and its variants in Canada. Self-isolation is...

26 nov 2021
Public health authorities in South Africa have confirmed that a new COVID-19 variant of concern (B.1.1.529) has been detected in that country. Over the past 24 hours, this variant ? named Omicron by the World Health Organization ? has also been...

26 nov 2021
CARESPAN HEALTH, INC. (formerly Dynamo Capital Corp.) ("CareSpan" or the "Company") is pleased to announce that, subject to the approval of the TSX Venture Exchange (the "TSX-V"), it has engaged the services of Generation IACP Inc. ("Generation") to...

26 nov 2021
Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing "Psychedelics to Therapeuticstm", is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved...



News published on 21 october 2021 at 10:05 and distributed by: